KalVista Pharmaceuticals, Inc. presents new data on patient-preferred on-demand treatment measures in HAE, and on the effects that the disease has on quality of life for people living with HAE, at the 2022 HAEi Global Leadership Workshop in Frankfurt, Germany.
KalVista presents supportive data for the use of the Patient Global Impression of Change (PGI-C) scale as a clinical endpoint to assess the efficacy of on-demand treatments for HAE attacks. Qualitative interviews with people with HAE demonstrated clear preference for the PGI-C (>70%,) over other scales as a measurement tool for patient outcomes. These findings are consistent with post hoc analyses of the KalVista phase 2 clinical trial for sebetralstat, which found PGI-C to be a clinically meaningful measure of efficacy for on-demand treatment of HAE attacks. The combination of clinical meaningfulness and patient preference led KalVista to choose PGI-C as the primary outcome measure for the ongoing phase 3 KONFIDENT clinical trial.
A second KalVista presentation highlights the significant impact that HAE attacks have on the mental health, daily activities, and quality of life of people living with HAE. This research found that a majority of people with HAE missed out on important events in their lives due to anxiety associated with unpredictability of HAE attacks and that almost half the time, patients feel “less than their 100% self” because of HAE.
“Despite many years of research in HAE, we are still gaining new insights on the impact of HAE attacks on the lives of people with the disease,” says Andrew Crockett, CEO of KalVista. “The goal of this and other research we conduct is to better understand the consequences of HAE and to learn how improve the treatment experience for these patients with our pipeline of oral therapies.”
(Source: KalVista)
